AI-Powered Insights Revolutionizing Pharma BD Deals

AI-Powered Insights: Revolutionizing Pharma BD Deals
Tuesday 11th June 2024
2:00 PM BST
A panel discussion with:
Roby Kanichay, Head of Technologies and Externalizations Business Development, Merck
David Linson, Senior Director-Business Operations and Intelligence, Eli Lilly
Alexandria Hall, Head of Industry, LifeSciences, Alphasense
Ivan Griffin, Co-Founder, BenevolentAl
Steve Lehmann, Director, Venture Operations, Portal Innovations
In the dynamic landscape of pharmaceutical business development (BD), the integration of artificial intelligence (AI) has emerged as a transformative force, reshaping traditional approaches to deal-making. AI-powered insights offer unparalleled capabilities in data analysis, predictive modeling, and decision support, empowering pharmaceutical companies to navigate complex deal structures with precision and agility. This panel discussion delves into the profound impact of AI on pharma BD deals, exploring how advanced analytics and machine learning algorithms are revolutionizing the negotiation process, driving strategic partnerships, and unlocking new avenues for growth and innovation.
Harnessing data intelligence for strategic decision-making
Optimizing deal valuation and risk assessment with predictive analytics
Enhancing due diligence and partner selection processes
Driving innovation and strategic partnerships through AI collaboration